Classification Term: 168146

Prostaglandins [FA0301] (ontology term: eba84115000c6a869996a252feeabc55)

Prostaglandins [FA0301]

found 141 associated metabolites at sub_class metabolite taxonomy ontology rank level.

Ancestor: Eicosanoids [FA03]

Child Taxonomies: There is no child term of current ontology term.

Prostaglandin E1

7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]heptanoic acid

C20H34O5 (354.24061140000003)


Prostaglandin E1 (PGE1) is a potent endogenous vasodilator agent that increases peripheral blood flow. It inhibits platelet aggregation and has many other biological effects such as bronchodilation, mediation of inflammation, and various protective functions. The protective action of PGE1 has been shown on both experimental animal models of liver injury and patients with fulminant viral hepatitis. PGE1-treated cirrhotic rats had less hepatosplenomegaly, lower serum alanine aminotransferase levels and portal pressures, and higher arterial pressure than placebo-treated cirrhotic rats. There are several mechanisms of PGE1 hepatic cytoprotection: inhibiting T-cell mediated cytotoxicity, enhancing DNA synthesis of the injured liver after partial hepatectomy by stimulating cyclic AMP production, increasing ATP level in hepatic tissue to accelerate the recovery of mitochondrial respiratory function after reperfusion, and stabilizing membrane microviscosity. PGE1 is a prostanoid. The term prostanoid collectively describes prostaglandins, prostacyclins, and thromboxanes. Prostanoids are a subclass of the lipid mediator group known as eicosanoids. They are derived from C-20 polyunsaturated fatty acids, mainly dihomo-γ-linolenic (20:3n-6), arachidonic (20:4n-6), and eicosapentaenoic (20:5n-3) acids, through the action of cyclooxygenases-1 and -2 (COX-1 and COX-2) (PMID: 11819590, 16986207). Prostaglandins are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes), and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent and are able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis through receptor-mediated G-protein linked signalling pathways. Prostaglandin E1 (Alprostadil) is a prostanoid receptor ligand, with Kis of 1.1 nM, 2.1 nM, 10 nM, 33 nM and 36 nM for mouse EP3, EP4, EP2, IP and EP1, respectively. Prostaglandin E1 induces vasodilation and inhibits platelet aggregation. Prostaglandin E1 can be used as a vasodilator for the research of peripheral vascular diseases[1][2][3].

   

Prostaglandin F1a

7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]cyclopentyl]heptanoic acid

C20H36O5 (356.2562606)


Prostaglandin F1a is derived mainly from Prostaglandin E1, and is metabolized to 6-Keto Prostaglandin F1a. Prostaglandin F1a is excreted directly into the urine. Prostaglandin F1a contracts the circular muscle of the gut in opposition to the Prostaglandins of the E series. Prostaglandin F1a is a cytoprotector, protecting mucosal tissue from damage produced by ulcerogenic stimuli.Prostaglandins are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes), and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent, able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis, through receptor-mediated G-protein linked signalling pathways. Prostaglandin F1a is derived mainly from Prostaglandin E1, and is metabolized to 6-Keto Prostaglandin F1a. Prostaglandin F1a is excreted directly into the urine. Prostaglandin F1a contracts the circular muscle of the gut in opposition to the Prostaglandins of the E series. Prostaglandin F1a is a cytoprotector, protecting mucosal tissue from damage produced by ulcerogenic stimuli.

   

15-keto PGI2

(5Z,13E)-6,9alpha-epoxy-11alpha-hydroxy-15-oxoprosta-5,13-dienoic acid

C20H30O5 (350.209313)


   

Prostaglandin D3

(5Z)-7-[(1R,2R,5S)-5-Hydroxy-2-[(1E,3S,5Z)-3-hydroxyocta-1,5-dien-1-yl]-3-oxocyclopentyl]hept-5-enoic acid

C20H30O5 (350.209313)


Prostaglandin D3 (PGD3) is a prostanoid that has been identified as an inhibitor of human platelet aggregation and as a modulator of autonomic nerve transmission. Prostanoids are a subclass of the lipid mediator group known as eicosanoids. They derive from C-20 polyunsaturated fatty acids, mainly dihomo-gamma-linoleic (20:3n-6), arachidonic (20:4n-6), and eicosapentaenoic (20:5n-3) acids, through the action of cyclooxygenases-1 and -2 (COX-1 and COX-2). The reaction product of COX is the unstable endoperoxide prostaglandin H (PGH) that is further transformed into the individual prostanoids by a series of specific prostanoid synthases. Prostanoids are local-acting mediators formed and inactivated within the same or neighbouring cells prior to their release into circulation as inactive metabolites (15-keto- and 13,14-dihydroketo metabolites). Non-enzymatic peroxidation of arachidonic acid and other fatty acids in vivo can result in prostaglandin-like substances isomeric to the COX-derived prostaglandins that are termed isoprostanes. Prostanoids take part in many physiological and pathophysiological processes in practically every organ, tissue and cell, including the vascular, renal, gastrointestinal and reproductive systems. Their activities are mediated through prostanoid-specific receptors and intracellular signalling pathways, whilst their biosynthesis and action are blocked by nonsteroidal antiinflammatory drugs (NSAID). Isoprostanes are considered to be reliable markers of oxidant stress status and have been linked to inflammation, ischaemia-reperfusion, diabetes, cardiovascular disease, reproductive disorders and diabetes. (PMID: 16986207, 6252026, 6952267, 4019112, 6945633Prostaglandins are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes), and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent, able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis, through receptor-mediated G-protein linked signalling pathways. Prostaglandin D3 (PGD3) is a prostanoid that has been identified as an inhibitor of human platelet aggregation and as a modulator of autonomic nerve transmission. Prostanoids are a subclass of the lipid mediator group known as eicosanoids. They derive from C-20 polyunsaturated fatty acids, mainly dihomo-gamma-linoleic (20:3n-6), arachidonic (20:4n-6), and eicosapentaenoic (20:5n-3) acids, through the action of cyclooxygenases-1 and -2 (COX-1 and COX-2). The reaction product of COX is the unstable endoperoxide prostaglandin H (PGH) that is further transformed into the individual prostanoids by a series of specific prostanoid synthases. Prostanoids are local-acting mediators formed and inactivated within the same or neighbouring cells prior to their release into circulation as inactive metabolites (15-keto- and 13,14-dihydroketo metabolites). Non-enzymatic peroxidation of arachidonic acid and other fatty acids in vivo can result in prostaglandin-like substances isomeric to the COX-derived prostaglandins that are termed isoprostanes. Prostanoids take part in many physiological and pathophysiological processes in practically every organ, tissue and cell, including the vascular, renal, gastrointestinal and reproductive systems. Their activities are mediated through prostanoid-specific receptors and intracellular signalling pathways, whilst their biosynthesis and action are blocked by nonsteroidal antiinflammatory drugs (NSAID). Isoprostanes are considered to be reliable markers of oxidant stress status and have been linked to inflammation, ischaemia-reperfusion, diabetes, cardiovascular disease, reproductive disorders and diabetes. (PMID: 16986207, 6252026, 6952267, 4019112, 6945633

   

Prostaglandin A3

9-oxo-15S-hydroxy-5Z,10Z,13E,17Z-prostatetraenoic acid

C20H28O4 (332.19874880000003)


A member of the class of prostaglandins A that is prosta-5,10,13,17-tetraen-1-oic acid carrying oxo and hydroxy substituents at positions 9 and 15 respectively (the 5Z,13E,15S,17Z-stereoisomer).

   

Prostaglandin B3

9-oxo-15S-hydroxy-5Z,8(12),13E,17Z-prostatetraenoic acid

C20H28O4 (332.19874880000003)


A member of the class of prostaglandins A that is prosta-5,8(12),13,17-tetraen-1-oic acid carrying oxo and hydsroxy substituents at positions 9 and 15 respectively (the 5Z,13E,15S,17Z-stereoisomer).

   

Prostaglandin A1

9-oxo-15S-hydroxy-10Z,13E-prostadienoic acid

C20H32O4 (336.2300472)


Prostaglandin A1 is a prostaglandins A. It is a conjugate acid of a prostaglandin A1(1-).

   

Prostaglandin B2

15S-hydroxy-9-oxo-5Z,8(12),13E-prostatrienoic acid

C20H30O4 (334.214398)


   

Prostacyclin

6,9S-epoxy-11R,15S-dihydroxy-5Z,13E-prostadienoic acid

C20H32O5 (352.2249622)


CONFIDENCE standard compound; NATIVE_RUN_ID STD_neg_MSMS_1min0196.mzML; PROCESSING averaging of repeated ion fragments at 30.0 eV within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID STD_neg_MSMS_1min0196.mzML; PROCESSING averaging of repeated ion fragments at 20.0 eV within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID STD_neg_MSMS_1min0196.mzML; PROCESSING averaging of repeated ion fragments at 10.0 eV within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID QExHF03_NM_0000127.mzML; PROCESSING averaging of repeated ion fragments at 30.0 eV within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID QExHF03_NM_0000127.mzML; PROCESSING averaging of repeated ion fragments at 20.0 eV within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID QExHF03_NM_0000127.mzML; PROCESSING averaging of repeated ion fragments at 10.0 eV within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID QExHF03_NM_0000127.mzML; PROCESSING averaging of repeated ion fragments at 40.0 NCE within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID QExHF03_NM_0000127.mzML; PROCESSING averaging of repeated ion fragments at 30.0 NCE within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID QExHF03_NM_0000127.mzML; PROCESSING averaging of repeated ion fragments at 20.0 NCE within 5 ppm window [MS, MS:1000575, mean of spectra, ]

   

Prostaglandin H1

9α,11α-epidioxy-15S-hydroxy-prost-13E-en-1-oic acid

C20H34O5 (354.24061140000003)


A member of the class of prostaglandins H that is prostaglandin H2 lacking the double bond at position 5.

   

Prostaglandin I3

6,9S-epoxy-11R,15S-dihydroxy-15Z,13E,17Z-prostatrienoic acid

C20H30O5 (350.209313)


   

PGE1 alcohol

1,11R,15S-trihydroxy-13E-prosten-9-one

C20H36O4 (340.2613456)


   

15R-PGA2

9oxo-15R-hydroxy-5Z,10Z,13E-prostatrienoic acid

C20H30O4 (334.214398)


   

15R-PGD2

9S,15R-dihydroxy-11-oxo-5Z,13E-prostadienoic acid

C20H32O5 (352.2249622)


   

D17 PGE1

9-oxo-11R,15S-dihydroxy-13E,17Z-prostadienoic acid

C20H32O5 (352.2249622)


   

PGD2-EA

N-(9S,15S-dihydroxy-11-oxo-5Z,13E-prostadienoyl)-ethanolamine

C22H37NO5 (395.26715920000004)


   

Prostaglandin K1

9,11-dioxo-15S-hydroxy-prost-13E-enoic acid

C20H32O5 (352.2249622)


   

15d-PGA1

9-oxo-prosta-10,12Z,14E-trienoic acid

C20H30O3 (318.21948299999997)


   

15d-PGA2

9-oxo-prosta-5Z,10,12Z,14E-tetraenoic acid

C20H28O3 (316.2038338)


   

13,14-dihydro-15-keto-PGD2-d4

11,15-dioxo-9S-hydroxy-5Z-prostenoic acid-d4

C20H28D4O5 (356.250070912)


   

Prostaglandin J3

15S-hydroxy-11-oxo-5Z,9Z,13E,17Z-prostatetraenoic acid

C20H28O4 (332.19874880000003)


A member of the class of prostaglandins J that is (5Z,9Z,13E,17Z)-prostatetraenoic acid carrying hydroxy and oxo substituents at positions 11 and 15 respectively. An intermediate of specialised proresolving mediators

   

PGF2alpha-G

9S,11R,15S-trihydroxy-5Z,13E-prostadienoic acid 1(3)-glyceryl ester

C23H40O7 (428.277389)


   

PGD2-G

9S,15S-dihydroxy-11-oxo-5Z,13E-prostadienoic acid 1(3)-glyceryl ester

C23H38O7 (426.2617398)


   

PGE2-G

9-oxo-11R,15S-dihydroxy-5Z,13E-prostadienoic acid 1(3)-glyceryl ester

C23H38O7 (426.2617398)


   

PGH2-G

9S,11R-epidioxy-15S-hydroxy-5Z,13E-prostadienoic acid 1(3)-glyceryl ester

C23H38O7 (426.2617398)


   

PGF2alpha-d4

(Z)-3,3,4,4-tetradeuterio-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]cyclopentyl]hept-5-enoic acid

C20H30D4O5 (358.265720112)


   

PGD2-d4

(Z)-3,3,4,4-tetradeuterio-7-[(1R,2R,5S)-5-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-3-oxocyclopentyl]hept-5-enoic acid

C20H28D4O5 (356.250070912)


   

PGE2-d4

(Z)-3,3,4,4-tetradeuterio-7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid

C20H28D4O5 (356.250070912)


   

Prostaglandin K2

(Z)-7-[(1R,2R)-2-[(E,3S)-3-hydroxyoct-1-enyl]-3,5-dioxocyclopentyl]hept-5-enoic acid

C20H30O5 (350.209313)


   

bicyclo-PGE2

(Z)-7-[(1R,3aS,7aS)-4-butyl-2,5-dioxo-3,3a,4,6,7,7a-hexahydro-1H-inden-1-yl]hept-5-enoic acid

C20H30O4 (334.214398)


   

PGE2-EA

(Z)-N-(2-hydroxyethyl)-7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]hept-5-enamide

C22H37NO5 (395.26715920000004)


   

Unoprostone

(+)-(Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl)-5-heptenoic acid;(5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]hept-5-enoic acid

C22H38O5 (382.2719098)


S - Sensory organs > S01 - Ophthalmologicals > S01E - Antiglaucoma preparations and miotics > S01EE - Prostaglandin analogues C78568 - Prostaglandin Analogue

   

Prostaglandin M

7R-hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid

C16H24O7 (328.1521954)


   

Dihomo-PGI2

6,9S-epoxy-11R,15S-dihydoxy-5Z,13E-1a,1b-dihomo-prostadienoic acid

C22H36O5 (380.2562606)


   

11beta-PGF2alpha-EA

N-(9S,11S,15S-trihydroxy-5Z,13E-prostadienoyl)-ethanolamine

C22H39NO5 (397.2828084)


   

PGD2-dihydroxypropanylamine

N-(1,3-dihydroxypropan-2-yl)-9S,15S-dihydroxy-11-oxo-5Z,13E-prostadienoyl amine

C23H39NO6 (425.2777234)


   

PGE2-dihydroxypropanylamine

N-(1,3-dihydroxypropan-2-yl)-9-oxo-11R,15S-dihydroxy-5Z,13E-prostadienoyl amine

C23H39NO6 (425.2777234)


   

PGF2alpha-dihydroxypropanylamine

N-(1,3-dihydroxypropan-2-yl)-9S,11R,15S-trihydroxy-5Z,13E-prostadienoyl amine

C23H41NO6 (427.29337260000005)


   

PGE1-EA

N-(9-oxo-11R,15S-dihydroxy-13E-prostenoyl)-ethanolamine

C22H39NO5 (397.2828084)


   

Dinor-PGE2

2,3-dinor-9-oxo-11R,15S-dihydroxy-5Z,13E-prostadienoic acid

C18H28O5 (324.1936638)


   

Dinor-PGD2

2,3-dinor-9S,15S-dihydroxy-11-oxo-5Z,13E-prostadienoic acid

C18H28O5 (324.1936638)


   

PGI2-EA

N-(6,9S-epoxy-11R,15S-dihydoxy-5Z,13E-prostadienoyl)-ethanolamine

C22H37NO5 (395.26715920000004)


   

PGH2-EA

N-(9S,11R-epidioxy-15S-hydroxy-5Z,13E-prostadienoyl)-ethanolamine

C23H39NO4 (393.28789340000003)


   

FA 20:1

17-methyl-trans-4,5-methyleneoctadecanoic acid

C20H38O2 (310.28716479999997)


Paullinic acid is a long-chain fatty acid that has been detected in multiple biofluids, such as blood and urine.

   

FA 20:4;O3

4-((1S,2S,5R)-5-hydroxy-2-((S,1E,5Z)-3-hydroxyundeca-1,5-dien-1-yl)-3-oxocyclopentyl)butanoic acid

C20H32O5 (352.2249622)


D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D000893 - Anti-Inflammatory Agents D018501 - Antirheumatic Agents

   

FA 22:4;O4

methyl 8-[3,5-epidioxy-2-(3-hydroperoxy-1-pentenyl)-cyclopentyl]-octanoate

C22H36O6 (396.2511756)


   

FA 18:3;O3

8-((1R,2S,3S)-3-hydroxy-2-((R,E)-3-hydroxypent-1-en-1-yl)-5-oxocyclopentyl)octanoic acid

C18H30O5 (326.209313)


   

FA 20:5;O2

4-((1R,5S)-5-((R,1E,5Z)-3-hydroxyundeca-1,5-dien-1-yl)-4-oxocyclopent-2-en-1-yl)butanoic acid

C20H30O4 (334.214398)


An oxylipin that is the (5S,6S)-epoxy-(15S)-hydroxy derivative of 7E,9E,11Z,13E-icosa-7,9,11,13-tetraenoic acid. D000890 - Anti-Infective Agents > D000998 - Antiviral Agents D000970 - Antineoplastic Agents

   

FA 20:4;O2

(5S,12R,6E,8Z,10E,14Z)-5,12-dihydroxy-6,8,10,14-eicosatetraenoic acid;(5S,6E,8Z,10E,12R,14Z)-5,12-dihydroxyeicosa-6,8,10,14-tetraenoic acid;(6E,8Z)-LTB4;5(S),12(R)-dihydroxy-6(E),8(Z),10(E),14(Z)-eicosatetraenoic acid;5(S),12(R)-dihydroxy-6(E),8(Z),10(E),14(Z)-icosatetraenoic acid;Delta(6)-trans,Delta(8)-cis-LTB4

C20H32O4 (336.2300472)


   

FA 18:2;O3

8-((1S,2R,3S,5R)-3,5-dihydroxy-2-((S,E)-3-hydroxypent-1-en-1-yl)cyclopentyl)octanoic acid

C18H32O5 (328.2249622)


   

FA 20:3;O2

(5R,8E,10E,12R,14Z)-5,12-dihydroxyicosa-8,10,14-trienoic acid

C20H34O4 (338.24569640000004)


   

FA 21:4;O3

17R,18R-dihydroxy-14S-methoxy-5Z,8Z,11Z,15E-eicosatetraenoic acid

C21H34O5 (366.24061140000003)


   

FA 20:3;O4

(S)-5-hydroxy-5-((2S,4S,5S)-4-hydroxy-5-((S,1E,5Z)-3-hydroxyundeca-1,5-dien-1-yl)tetrahydrofuran-2-yl)pentanoic acid

C20H34O6 (370.2355264)


   

Cyclosin

9S,11R,15S-trihydroxy-5Z,13E-prostadienoic acid

C20H34O5 (354.24061140000003)


G - Genito urinary system and sex hormones > G02 - Other gynecologicals > G02A - Uterotonics > G02AD - Prostaglandins D012102 - Reproductive Control Agents > D000019 - Abortifacient Agents D012102 - Reproductive Control Agents > D010120 - Oxytocics C78568 - Prostaglandin Analogue Dinoprost (Prostaglandin F2α) is an orally active, potent prostaglandin F (PGF) receptor (FP receptor) agonist. Dinoprost is a luteolytic hormone produced locally in the endometrial luminal epithelium and corpus luteum (CL). Dinoprost plays a key role in the onset and progression of labour[1][2].

   

Prostin E2

9-oxo-11R,15S-dihydroxy-5Z,13E-prostadienoic acid

C20H32O5 (352.2249622)


G - Genito urinary system and sex hormones > G02 - Other gynecologicals > G02A - Uterotonics > G02AD - Prostaglandins D012102 - Reproductive Control Agents > D010120 - Oxytocics C78568 - Prostaglandin Analogue Prostaglandin E2 (PGE2) is a hormone-like substance that participate in a wide range of body functions such as the contraction and relaxation of smooth muscle, the dilation and constriction of blood vessels, control of blood pressure, and modulation of inflammation.

   

Prostaglandin D2

(5Z,13E,15S)-9alpha,15-Dihydroxy-11-oxoprosta-5,13-dienoate

C20H32O5 (352.2249622)


A member of the class of prostaglandins D that is prosta-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9 and 15 and an oxo group at position 11 (the 5Z,9alpha,13E,15S- stereoisomer).

   

Prostaglandin G2

9S,11R-epidioxy-15S-hydroperoxy-5Z,13E-prostadienoic acid

C20H32O6 (368.2198772)


D009676 - Noxae > D016877 - Oxidants > D010545 - Peroxides

   

Prostaglandin H2

9S,11R-epidioxy-15S-hydroxy-5Z,13E-prostadienoic acid

C20H32O5 (352.2249622)


D009676 - Noxae > D016877 - Oxidants > D010545 - Peroxides

   

6-keto PGE1

6,9-dioxo-11R,15S-dihydroxy-13E-prostenoic acid

C20H32O6 (368.2198772)


   

FA 20:4;O4

4-(3-{[(1S,2S,3S)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]methyl}oxiran-2-yl)butanoic acid

C20H32O6 (368.2198772)


D009676 - Noxae > D016877 - Oxidants > D010545 - Peroxides

   

Prostaglandin J2

11-oxo-15S-hydroxy-5Z,9,13E-prostatrienoic acid-cyclo[8S,12R]

C20H30O4 (334.214398)


A member of the class of prostaglandins J that consists of prosta-5,9,13-trien-1-oic acid substituted by an oxo group at position 11 and a hydroxy group at position 15 (the 5Z,13E,15S stereoisomer). D000970 - Antineoplastic Agents

   

FA 20:6;O

9-oxo-5E,10Z,14Z-prostatrienoic acid-1,4R-lactone-cyclo[8S,12R]

C20H28O3 (316.2038338)


D007155 - Immunologic Factors

   

dhk-PGD2

11,15-dioxo-9S-hydroxy-5Z-prostenoic acid

C20H32O5 (352.2249622)


   

PGF2beta

9R,11R,15S-trihydroxy-5Z,13E-prostadienoic acid

C20H34O5 (354.24061140000003)


   

15k-PGF2a

9S,11R-dihydroxy-15-oxo-5Z,13E-prostadienoic acid

C20H32O5 (352.2249622)


   

FA 20:3;O3

7-[(1R,2R,3S,5S)-3,5-dihydroxy-2-[(3S)-3-hydroxyoct-1-enyl]cyclopentyl]hept-5-enoic acid

C20H34O5 (354.24061140000003)


D012102 - Reproductive Control Agents > D000019 - Abortifacient Agents D012102 - Reproductive Control Agents > D010120 - Oxytocics

   

FA 20:5;O3

(5R,6E,8Z,10E,12E,14R,15R,17Z)-5,14,15-trihydroxyicosa-6,8,10,12,17-pentaenoic acid

C20H30O5 (350.209313)


   

FA 16:4;O5

9S-hydroxy-11,15-dioxo-2,3,4,5-tetranor-prostan-1,20-dioic acid

C16H24O7 (328.1521954)


   

PROSTAGLANDIN A2

9-oxo-15S-hydroxy-5Z,10Z,13E-prostatrienoic acid

C20H30O4 (334.214398)


   

11beta-PGF2

9S,11S,15S-trihydroxy-5Z,13E-prostadienoic acid

C20H34O5 (354.24061140000003)


   

6k-PGF1alpha-d4

9S,11R,15S-trihydroxy-6-oxo-13E-prostenoic acid (3,3,4,4-d4)

C20H30D4O6 (374.260635112)


   

FA 20:2;O4

9S,11R,15S,19R-tetrahydroxy-13E-prostaenoic acid

C20H36O6 (372.2511756)


   

Prostaglandin D1

9S,15S-dihydroxy-11-oxo-13E-prostaenoic acid

C20H34O5 (354.24061140000003)


   

FA 22:4;O3

20a,20b-dihomo-9-oxo-11R,15S-dihydroxy-5Z,13E-prostadienoic acid

C22H36O5 (380.2562606)


   

Doproston

(13E,15S)-15-Hydroxy-9-oxoprost-13-en-1-oic acid

C20H34O4 (338.24569640000004)


D005765 - Gastrointestinal Agents > D000897 - Anti-Ulcer Agents

   

15R-PGE1

9-oxo-11R,15R-dihydroxy-13E-prostaenoic acid

C20H34O5 (354.24061140000003)


   

FA 21:3;O3

9S,11R,15R-trihydroxy-15-methyl-5Z,13E-prostadienoic acid

C21H36O5 (368.2562606)


   

FA 22:3;O3

1a,1b-dihomo-11S,13R,17S-trihydroxy-7Z,15E-prostadienoic acid-cyclo[10S,14R]

C22H38O5 (382.2719098)


   

FA 21:4;O2

10S-hydroxy-(11S,12S)-epoxy-(5Z,8Z,14Z)-eicosatrienoic acid methyl esther

C21H34O4 (350.24569640000004)


   

FA 23:4;O2

9-methylene-11R,15S-dihydroxy-16,16-dimethyl-5Z,13E-prostadienoic acid

C23H38O4 (378.2769948)


   

11beta-PGE2

9-oxo-11S,15S-dihydroxy-5Z,13E-prostadienoic acid-cyclo[8R,12R]

C20H32O5 (352.2249622)


   

FA 22:4;O2

9-oxo-15R-hydroxy-16,16-dimethyl-10Z,13E-prostadienoic acid

C22H36O4 (364.2613456)


   

FA 22:8;O3

9-oxo-11R,15S-dihydroxy-16-phenyl-17,18,19,20-tetranor-5Z,13E-prostadienoic acid

C22H28O5 (372.1936638)


   

FA 23:8;O3

9-oxo-11R,15S-dihydroxy-17-phenyl-18,19,20-trinor-5Z,13E-prostadienoic acid

C23H30O5 (386.209313)


   

FA 20:2;O2

9R,15S-dihydroxy-13E-prostaenoic acid

C20H36O4 (340.2613456)


   

PGF1beta

9R,11R,15S-trihydroxy-13E-prostaenoic acid

C20H36O5 (356.2562606)


   

FA 21:2;O2

1-methoxy-9S,11R,15S-trihydroxy-5Z,13E-prostadiene

C21H38O4 (354.2769948)


   

PGF2alpha dimethyl amide

N,N-dimethyl-9S,11R,15S-trihydroxy-5Z,13E-prostadien-1-amide

C22H39NO4 (381.28789340000003)


   

PMF2alpha

N-(9S,11R,15S-trihydroxy-5Z,13E-prostadienoyl)-ethanolamine

C22H39NO5 (397.2828084)


   

FA 23:3;O3

1a,1b-dihomo-8,12,14-trihydroxy-5Z,9E-prostadienoic acid-cyclo[11,15]

C23H40O5 (396.28755900000004)


   

FA 20:2;O3

13,14-dihydro-15-keto-Prostaglandin F1alpha

C20H36O5 (356.2562606)


   

FA 23:7;O3

9S,11R,15S-trihydroxy-17-phenyl-18,19,20-trinor-5Z,13E-prostadienoic acid

C23H32O5 (388.2249622)


   

FA 22:5;O2

9oxo-15R-hydroxy-16,16-dimethyl-5Z,10Z,13E-prostatrienoic acid

C22H34O4 (362.24569640000004)


   

FA 18:3;O4

9S,11,15S-trihydroxy-2,3-dinor-thromboxa-5Z,13E-dien-1-oic acid

C18H30O6 (342.204228)


   

15R-PGE2

9-oxo-11R,15R-dihydroxy-5Z,13E-prostadienoic acid-cyclo[8R,12R]

C20H32O5 (352.2249622)


   

FA 23:4;O4

methyl 9S,15S-dihydroxy-11R-acetoxy-5Z,13E-prostadienoate

C23H38O6 (410.2668248)


   

FA 24:5;O6

9S,15S-dihydroxy-11R,18-diacetoxy-5Z,13E-prostadienoic acid

C24H38O8 (454.2566548)


   

FA 25:5;O6

methyl 9S,15S-dihydroxy-11R,18-diacetoxy-5Z,13E-prostadienoate

C25H40O8 (468.272304)


   

FA 21:5;O2

Methyl-(10R)-hydroxy-(11S,12S)-epoxy-(5Z,8Z,14Z,17Z)-eicosa-(5,8,14,17)-tetraenoate

C21H32O4 (348.2300472)


   

PGF2alpha alcohol

1,9S,11R,15S-tetrahydroxy-5Z,13E-prostadiene

C20H36O4 (340.2613456)


   

PGE2alpha dimethyl amine

1-dimethylamino-9S,11R,15S-trihydroxy-5Z,13E-prostadiene

C22H41NO3 (367.3086276)


   

17-phenyl-trinor-PGF2alpha amide

9S,11R,15S-trihydroxy-17-phenyl-18,19,20-trinor-5Z,13E-prostadienamide

C23H33NO4 (387.2409458000001)


   

FA 26:7;O3

isopropyl 9S,11R,15S-trihydroxy-17-phenyl-18,19,20-trinor-5Z,13E-prostadienoate

C26H38O5 (430.2719098)


   

6alpha-PGI1

6R,9S-epoxy-11R,15S-dihydroxy-13E-prostaenoic acid

C20H34O5 (354.24061140000003)


   

6beta-PGI1

6S,9R-epoxy-11R,15S-dihydroxy-13E-prostaenoic acid

C20H34O5 (354.24061140000003)


   

Prostaglandin B1

9-oxo-15S-hydroxy-8(12),13E-prostadienoic acid

C20H32O4 (336.2300472)


A member of the class of prostaglandins B that is prosta-8(12),13-dien-1-oic acid carrying oxo and hydroxy substituents at positions 9 and 15 respectively (the 13E,15S-stereoisomer).

   

Prostaglandin C2

9-oxo-15S-hydroxy-5Z,11Z,13E-prostatrienoic acid

C20H30O4 (334.214398)


A member of the class of prostaglandins C that is prosta-5,11,13-trien-1-oic acid carrying oxo and hydroxy substituents at positions 9 and 15 respectively (the 5Z,13E,15S-stereoisomer).

   

Prostaglandin E3

9-oxo-11R,15S-dihydroxy-5Z,13E,17Z-prostatrienoic acid

C20H30O5 (350.209313)


   

PGF3alpha

9S,11R,15S-trihydroxy-5Z,13E,17Z-prostatrienoic acid

C20H32O5 (352.2249622)


   

FA 16:3;O5

9S,11R-dihydroxy-15-oxo-2,3,4,5-tetranor-prostan-1,20-dioic acid

C16H26O7 (330.16784459999997)


   

Prostaglandin C1

9-oxo-15S-hydroxy-11Z,13E-prostadienoic acid

C20H32O4 (336.2300472)


   

FA 22:6;O

(+/-)-20-hydroxy-4Z,7Z,10Z,13Z,16Z,18E-docosahexaenoic acid

C22H32O3 (344.23513219999995)


   

PGF1a alcohol

1,9S,11R,15S-tetrahydroxy-13E-prostaene

C20H38O4 (342.2769948)


   

Tetranor-PGEM-d6

11R-hydroxy-9,15-dioxo-2,3,4,5-tetranor-prostan-1,20-dioic acid-d6

C16H16D6O7 (332.174209268)


   

11beta-PGF2alpha-d4

9S,11S,15S-trihydroxy-5Z,13E-prostadienoic acid-d4

C20H30D4O5 (358.265720112)


   

15-deoxy-delta-12,14-PGJ2-d4

11-oxo-5Z,9,12E,14Z-prostatetraenoic acid-d4

C20H24D4O3 (320.228942512)


   

13,14-dihydro-15-keto-PGF2alpha-d4

13,14-dihydro-15-keto-Prostaglandin F2alpha-d4

C20H30D4O5 (358.265720112)


   

FA 23:3;O5

9S,11R,15S-trihydroxy-5Z,13E-prostadienoic acid 2-glyceryl ester

C23H40O7 (428.277389)


   

FA 23:4;O5

9S,11R-epidioxy-15S-hydroxy-5Z,13E-prostadienoic acid 2-glyceryl ester

C23H38O7 (426.2617398)


   

FA 23:3;O6

6-oxo-9S,11R,15S-trihydroxy-13E-prostenoic acid 1(3)-glyceryl ester

C23H40O8 (444.272304)


   

FA 20:6;O2

5S,6S-epoxy,18R-hydroxy-7E,9E,11Z,14Z,16E-eicosapentaenoic acid

C20H28O4 (332.19874880000003)


   

FA 23:5;O4

methyl 9-oxo-11R-hydroxy-15R-acetoxy-5Z,13E-prostadienoate

C23H36O6 (408.2511756)


   

FA 23:6;O3

methyl 9-oxo-11R-hydroxy-15R-acetoxy-5Z,10,13E-prostatrienoate

C23H34O5 (390.24061140000003)


   

PGF2alpha-EA(d4)

N-(9S,11R,15S-trihydroxy-5Z,13E-prostadienoyl)-ethanolamine(d4)

C22H35D4NO5 (401.30791711200004)


   

FA 16:3;O3

2,3,4,5-tetranor-9S,15S-dihydroxy-11-oxo-13E-prostenoic acid

C16H26O5 (298.1780146)


   

FA 16:2;O3

2,3,4,5-tetranor-9S,11R,15S-trihydroxy-13E-prostenoic acid

C16H28O5 (300.1936638)


   

Sarcoehrendin A

methyl 9S,hydroxy-11R,15S,18-triacetoxy-5Z,13E-prostadienoate

C27H42O9 (510.28286820000005)


   

Sarcoehrendin B

methyl 9S,11R,15S,18-tetraacetoxy-5Z,13E-prostadienoate

C29H44O10 (552.2934324)


   

Sarcoehrendin C

methyl 15S-hydroxy-9S,11R,18-triacetoxy-5Z,13E-prostadienoate

C27H42O9 (510.28286820000005)


   

Sarcoehrendin D

methyl 18-oxo-9S,11R,15S-triacetoxy-5Z,13E-prostadienoate

C27H40O9 (508.26721900000007)


   

Sarcoehrendin E

methyl 18-oxo-9S,15S-dihydroxy-11R-acetoxy-5Z,13E-prostadienoate

C23H36O7 (424.2460906)


   

Sarcoehrendin F

methyl 18-oxo-9S,hydroxy-11R,15S-diacetoxy-5Z,13E-prostadienoate

C25H38O8 (466.2566548)


   

Sarcoehrendin H

18-oxo-9S,hydroxy-11R,15S-diacetoxy-5Z,13E-prostadienoic acid

C24H36O8 (452.2410056)


   

Sarcoehrendin G

18-oxo-9S,15S-dihydroxy-11R-acetoxy-5Z,13E-prostadienoic acid

C22H34O7 (410.2304414)


   

Sarcoehrendin I

methyl-9S-hydroxy-11R,15S-diacetoxy-6Z,13E-prostadienoate

C25H40O7 (452.277389)


   

Sarcoehrendin J

methyl 9S-hydroxy-11R,15S-diacetoxy-13E-prostenoate

C25H42O7 (454.2930382)


   

5E-PGB2

15S-hydroxy-9-oxo-5E,8(12),13E-prostatrienoic acid

C20H30O4 (334.214398)


   

15dPGJ2-GS

11-oxo-9-(S-glutathionyl)-5Z,12E,14E-prostatetraenoic acid

C30H45N3O9S (623.287636)


   

15-deoxy-PGD2

(5Z)-7-[(1R,2E,5S)-5-hydroxy-2-[(2E)-oct-2-en-1-ylidene]-3-oxocyclopentyl]hept-5-enoic acid

C20H30O4 (334.214398)


15-deoxy-PGD2 is classified as a member of the Prostaglandins and related compounds. Prostaglandins and related compounds are unsaturated carboxylic acids consisting of a 20 carbon skeleton that also contains a five member ring, and are based upon the fatty acid arachidonic acid. 15-deoxy-PGD2 is considered to be practically insoluble (in water) and acidic. 15-deoxy-PGD2 is an eicosanoid lipid molecule

   

PGF1alpha

(13E,15S)-9alpha,11alpha-9,11,15-Trihydroxyprost-13-en-1-Oic acid

C20H36O5 (356.2562606)


   

Prostaglandin D3

9S,15S-dihydroxy-11-oxo-5Z,13E,17Z-prostatrienoic acid

C20H30O5 (350.209313)


A member of the class of prostaglandins D that is prosta-5,13,17-trien-1-oic acid substituted by hydroxy groups at positions 9 and 15 and an oxo group at position 11 (the 5Z,13E,15S,17Z-stereoisomer).